Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Kite Pharma Inc.
DescriptionT cell receptor immunotherpay targeting NY-ESO-1
Molecular Target Cancer/testis antigen 1B (NY-ESO-1) (CTAG1B)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat metastatic cancer other than melanoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today